 Prostatic Hyperplasia
"Prostatic Hyperplasia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Descriptor ID |
D011470
|
| MeSH Number(s) |
C12.294.565.500
|
| Concept/Terms |
Adenoma, Prostatic- Adenoma, Prostatic
- Adenomas, Prostatic
- Prostatic Adenomas
- Prostatic Adenoma
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Hyperplasia".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Hyperplasia".
This graph shows the total number of publications written about "Prostatic Hyperplasia" by people in UAMS Profiles by year, and whether "Prostatic Hyperplasia" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 2 | 0 | 2 | | 2021 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2015 | 2 | 2 | 4 | | 2014 | 0 | 2 | 2 | | 2013 | 4 | 2 | 6 | | 2012 | 1 | 0 | 1 | | 2011 | 4 | 0 | 4 | | 2010 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2008 | 3 | 2 | 5 | | 2006 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostatic Hyperplasia" by people in Profiles over the past ten years.
-
Khalil MI, Chase A, Joseph JV, Ghazi A. Standard Multiport vs Single-Port Robot-Assisted Simple Prostatectomy: A Single-Center Initial Experience. J Endourol. 2022 08; 36(8):1057-1062.
-
Mostafa MM, Patil N, Khalil M, Elgammal MA, Mahdy A. Is Holmium Laser Enucleation of Prostate equally effective in management of benign prostatic hyperplasia patients with either voiding or storage lower urinary tract symptoms? A comparative study. Arch Ital Urol Androl. 2022 Jun 29; 94(2):174-179.
-
Moverman MA, Bruha MJ, Pagani NR, Puzzitiello RN, Menendez ME, Barnes CL. Perioperative Medical Optimization of Symptomatic Benign Prostatic Hyperplasia Is an Economically Justified Infection Prevention Strategy in Total Joint Arthroplasty. J Arthroplasty. 2021 07; 36(7):2551-2557.
-
Sørensen TT, Horváth-Puhó E, Nørgaard M, Ehrenstein V, Henderson VW. Risk of amyotrophic lateral sclerosis and other motor neuron disease among men with benign prostatic hyperplasia: a population-based cohort study. BMJ Open. 2019 07 04; 9(7):e030015.
-
Vouri SM, Strope SA, Olsen MA, Xian H, Schootman M. Antimuscarinic Use in Men Treated With Bladder Outlet Obstruction Medication Therapy. Urology. 2018 Dec; 122:76-82.
-
Cakiroglu B, Hazar AI, Sinanoglu O, Arda E, Ekici S. Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation. Arch Ital Urol Androl. 2017 Mar 31; 89(1):31-33.
-
You J, Willcox M, Fitzgerald A, Schiller B, Cozzi PJ, Russell PJ, Walsh BJ, Wasinger VC, Graham PH, Li Y. Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling. Anal Biochem. 2016 Mar 01; 496:30-4.
-
Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. J Urol. 2016 06; 195(6):1825-9.
-
de la Rosette J, Elhilali M, Naito S, Unal D, Razvi H, Liatsikos E, Bachmann A, Tubaro A, Alivizatos G, Mak SK, Badlani G, Eltahawy E, Wong C, Telich Vidal M, Te A, d'Ancona F, Arum CJ, Gutierrez J. Clinical Research Office of the Endourological Society Global GreenLight Laser Study: Outcomes from a contemporary series of 713 patients. Int J Urol. 2015 Dec; 22(12):1124-30.
-
Wong RL, Wang Q, Treviño LS, Bosland MC, Chen J, Medvedovic M, Prins GS, Kannan K, Ho SM, Walker CL. Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate. Epigenetics. 2015; 10(2):127-34.
-
Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 2015 Feb 15; 136(4):875-9.
-
Upreti R, Hughes KA, Livingstone DE, Gray CD, Minns FC, Macfarlane DP, Marshall I, Stewart LH, Walker BR, Andrew R. 5a-reductase type 1 modulates insulin sensitivity in men. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1397-406.
-
Kaplan SA, Lee JY, O'Neill EA, Meehan AG, Kusek JW. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male. 2013 Dec; 16(4):169-72.
-
Itah Z, Oral O, Perk OY, Sesen M, Demir E, Erbil S, Dogan-Ekici AI, Ekici S, Kosar A, Gozuacik D. Hydrodynamic cavitation kills prostate cells and ablates benign prostatic hyperplasia tissue. Exp Biol Med (Maywood). 2013 Nov 01; 238(11):1242-50.
-
Penugonda K, Lindshield BL. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients. 2013 Sep 13; 5(9):3617-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|